Novel technology allows for noninvasive imaging of prostate cancer

April 2, 2012

Use of a novel, noninvasive imaging tool allowed researchers to measure free prostate-specific antigen in prostate cancer models and to visualize bone metastasis in a tumor-specific manner, according to results published in Cancer Discovery, a journal of the American Association for Cancer Research.

Results of this paper were presented here at an AACR Annual Meeting 2012 press conference on Saturday, March 31, 2012, at 4:00 p.m. CT in Room 20 A/B/C of the Hyatt Conference Center, adjacent to McCormick Place.

If further validated, the use of this tool, a prostate cancer-specific radiotracer, could potentially aid in treatment planning on an individualized patient basis, according to Michael J. Evans, Ph.D., research fellow in the Human and Program at Memorial Sloan-Kettering Cancer Center in New York, N.Y., and colleagues.

A radiotracer is a small amount of a compound that has been “tagged” with a radionuclide. Patients are injected with the radiotracer, which aids in visualizing the tumor using positron emission tomography (PET).

In this study, Evans and colleagues examined the effects of 89Zr-5A10, the first radiotracer designed specifically to target free (PSA), a known biomarker of that provides a more accurate measure of risk when compared with serum PSA.

“Once injected, the use of 89Zr-5A10 allows physicians to measure different biological properties among metastatic lesions within the same patient, which a serum biomarker cannot achieve,” Evans said.

Researchers tested the utility of 89Zr-5A10 in a group of male mice with PSA-positive prostate cancer. The radiotracer localized to the tissue of castration-resistant prostate cancer, a state of the disease where serum PSA does not always reflect clinical outcomes, and sensitively measured declines in PSA expression induced by therapeutic intervention with the antiandrogen drug MDV3100.

The also helped researchers identify metastatic bone lesions related to the primary prostate cancer. Traditional bone scans are unable to discriminate between malignant and nonmalignant lesions.

If translated to humans, this PET agent could help to stage prostate cancer, streamline the evaluation of prostate cancer therapies and aid in clinical trial management.

“The ultimate goal is to be able to predict the response of patients to new and existing therapies at an early stage, thereby personalizing their treatment and improving outcomes,” Evans said.

Given the success of this preclinical work, Evans and colleagues hope to translate the 89Zr-5A10 platform for a human trial by 2013.

Explore further: PSA test for men could get a second life for breast cancer in women

Related Stories

PSA test for men could get a second life for breast cancer in women

July 13, 2011
The widely known PSA blood test for prostate cancer in men may get a second life as a much-needed new test for breast cancer, the most common form of cancer in women worldwide, scientists are reporting in a new study in the ...

When rising PSA means prostate cancer is in patient's future

May 18, 2011
A man's rising PSA (prostate-specific antigen) level over several years – which had been seen as a possible warning sign of prostate cancer – has recently come under fire as a screening test because it sometimes ...

New prostate cancer test gives more accurate diagnosis

April 6, 2011
In a large multi-center clinical trial, a new PSA test to screen for prostate cancer more accurately identified men with prostate cancer -- particularly the aggressive form of the disease -- and substantially reduced false ...

More aggressive treatment not necessary for men with a family history of prostate cancer

October 5, 2011
Approximately 10-20 percent of prostate cancer patients have a family history of the disease. There are three major factors that are used to evaluate the extent and aggressiveness of prostate cancer, help make treatment decisions, ...

Inflammation marker may guide prognosis for prostate cancer

September 28, 2011
(Medical Xpress) -- Current methods of prostate cancer detection, like the prostate-specific antigen (PSA) test, often fail to identify which cancers will prove fatal and which cancers will remain benign until a patient dies ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.